`Ex. 1042, Brenna Declaration
`
`(Ex. 1054; March 16, 2012 Declaration of Faustinus Yeboah, ’348
`
`
`
`Reexamination at ¶ 36.)
`
` Another Neptune declarant, Dr. Shahidi, also
`
`acknowledged that extractions resulting from the Beaudoin process contain the
`
`claimed phospholipids:
`
`As Beaudoin reports an oil potentially with a small amount of the
`
`phospholipid containing two of EPA and DHA (i.e. about 0.1 to 1% ), it is my
`
`opinion that this is not a biologically effective amount. As the claims of the ’348
`
`patent are directed to biologically effective amounts of this composition, they are
`
`distinct from Beaudoin.
`
`(Ex. 1056; March 16, 2012 Declaration of Fereidoon Shahidi, ’348
`
`Reexamination, at ¶ 22.)
`
`4.1.2.4.
`
`Conclusion on Obviousness
`
`(i) Claims 1-94 of the ’351 patent are obvious over Beaudoin I (Ex.
`
`1002) in view of Bergelson (Ex. 1017)
`
`384. Claims 1-94 are obvious over Beaudoin I in view of Bergelson.
`
`385. As established above, Beaudoin I provides each element of claims 1-
`
`94 either expressly or
`
`inherently. The declaratory evidence conclusively
`
`
`
`201
`
`00000201
`
`
`
`Inter Partes Review of US 8,278,351
`Ex. 1042, Brenna Declaration
`
`
`
`establishes the inherent presence of the claimed phospholipids in Beaudoin I
`
`extracts from both E. pacifica and E. superba.
`
`386. There are no data in the ‘351 patent that compares the biological
`
`effectiveness of the claimed phospholipids to phospholipids with only one EPA or
`
`DHA attached. Likewise, there are no data that establishes the criticality of any of
`
`the other components listed in the independent and dependent claims. The
`
`extraction methods described in ‘351 patent are essentially the same as described
`
`in Table 19 of Beaudoin I. Thus, the extracts disclosed in Beaudoin I would be
`
`very similar in composition to the ‘351 extracts and necessarily include the
`
`components listed in the independent and dependent claims. To the extent there
`
`are any differences, it would have been routine optimization to provide the claimed
`
`amounts of extract components absent a showing of criticality.
`
`387. Patentee has also argued that the Beaudoin I extracts are not suitable
`
`for human consumption because of the solvent content in the extracts. Bergelson
`
`discloses that is well known to remove solvent from lipid extracts under gentle
`
`conditions by rotary evaporation.
`
`388. Beaudoin I is directed to the production of phospholipid extracts from
`
`marine sources, including krill, for human consumption. Beaudoin I contains a
`
`detailed protocol for extraction in Table 19, specifying that solvent may be
`
`removed under reduced pressure. Bergelson teaches that solvent can be removed
`202
`
`
`
`00000202
`
`
`
`Inter Partes Review of US 8,278,351
`Ex. 1042, Brenna Declaration
`
`
`
`by rotary evaporation (i.e., under reduced pressure) under mild temperature
`
`conditions. Ex. 1002, p. 10-11. Thus, there is a motivation to combine the
`
`references. A person of ordinary skill in the art would be motivated to remove
`
`solvent from the krill extracts of Beaudoin I by rotary evaporation as described in
`
`Bergelson to provide a krill extract with a desired content of phospholipids, EPA
`
`and DHA as well as other components naturally present in krill and presented in
`
`the claims. The person of skill in the art would be motivated to remove solvent to
`
`levels suitable for human consumption as Beaudoin clearly teaches the desirability
`
`of krill oil for both oral administration and topical administration as a cosmetic.
`
`The person of skill in the art would likewise be motivated to process the extracts so
`
`as to maintain the phospholipid content (i.e., avoid phospholipid degradation)
`
`because Beaudoin I teaches the desirability of the recovery of total lipids.
`
`389. A person of skill in the art would have a reasonable expectation of
`
`success in arriving at the claimed invention because the methods of Beaudoin I are
`
`essentially the same as those described in the ‘351 patent. Thus, the concentration
`
`of lipids in the extracts resulting from the Beaudoin I extraction process would be
`
`essentially the same as the concentrations specified in the claims. The extracts
`
`could easily be made suitable for human consumption by rotary evaporation as
`
`described in Bergelson.
`
`
`
`203
`
`00000203
`
`
`
`Inter Partes Review of US 8,278,351
`Ex. 1042, Brenna Declaration
`
`
`
`(ii) Claims 1-94 are unpatentable under 35 USC 103(a) over Beaudoin I
`
`(Ex. 1002) in view of the 2001 Prospectus (Ex. 1011), 2001 Press Release (Ex.
`
`1012) and Bergelson (Ex. 1017)
`
`390. Claims 1- 94 are obvious over Beaudoin I in view of the 2001
`
`Prospectus, 2001 Press Release and Bergelson. As discussed above, Beaudoin I
`
`provides each element of claims 1-94 either expressly or inherently. The
`
`declaratory evidence conclusively establishes the inherent presence of the claimed
`
`phospholipids in Beaudoin I extracts from both E. pacifica and E. superba.
`
`391. In addition to its arguments that the Beaudoin I extracts do contain
`
`meaningful amounts the claimed phospholipids, Patentee has argued that the
`
`claimed phospholipids are absent in the Beaudoin I extracts because they were
`
`degraded by heating. The citation of the 2001 Prospectus and 2001 Press release
`
`address this alleged deficiency as they describe the Beaudoin I process is a “cold
`
`extraction” process. Following the Beaudoin I protocol and using solvent
`
`evaporation techniques known in the art (e.g., as described in Bergelson) would
`
`produce an undegraded krill oil. The 2001 Prospectus states that the Beaudoin
`
`I/OceanExtractTM process is a cold extraction process that preserves the
`
`biological activity of the lipid substances, results in minimal alterations to the
`
`lipids, and is suitable for human consumption. Ex. 1011 at 13. The 2001 Press
`
`Release states that the Beaudoin I/OceanExtractTM process is a “cold process that
`204
`
`
`
`00000204
`
`
`
`Inter Partes Review of US 8,278,351
`Ex. 1042, Brenna Declaration
`
`
`
`preserves the biological activity and stability of the nutritional qualities intrinsic to
`
`the most highly sought substances of Krill, such as its powerful antioxidants,
`
`phospholipids and Omega-3-6-9 fatty acids” and produces a krill extract suitable
`
`for human consumption. Ex. 1012 at 1. Thus, krill phospholipid extracts produced
`
`according to the Beaudoin I/OceanExtractTM process would be in all aspects
`
`identical to those claimed in the ‘351 patent. The disclosure of the 2001
`
`Prospectus and Press Release is entirely consistent with the protocols in Beaudoin I
`
`which describe the preferred extraction process which a) does not include a heating
`
`step and b) specifies cold conditions for extraction (i.e., 4oC).
`
`392. Beaudoin I is directed to the production of phospholipid extracts from
`
`marine sources, including krill, for human consumption. Beaudoin I contains a
`
`detailed protocol for extraction in Table 19, specifying that solvent may be
`
`removed under reduced pressure. The 2001 Prospectus and 2001 Press release
`
`state that the process disclosed in Beaudoin I and licensed from the University of
`
`Sherbrooke by Patentee is a cold extraction process. Bergelson teaches that
`
`solvent can be removed by rotary evaporation (i.e., under reduced pressure) under
`
`mild temperature conditions. Ex. 1017, p. 10-11. A person of ordinary skill in the
`
`art would be motivated to conduct extraction from krill under cold conditions and
`
`to remove solvent from the krill extracts of Beaudoin I by rotary evaporation as
`
`described in Bergelson to provide a krill extract with a desired content of
`205
`
`
`
`00000205
`
`
`
`Inter Partes Review of US 8,278,351
`Ex. 1042, Brenna Declaration
`
`
`
`phospholipids, claimed phospholipids, EPA and DHA as well as other components
`
`naturally present in krill and presented in the claims. The person of skill in the art
`
`would be motivated to remove solvent to levels suitable for human consumption as
`
`Beaudoin clearly teaches the desirability of krill oil for both oral administration
`
`and topical administration as a cosmetic. The person of skill in the art would
`
`likewise be motivated to process the extracts so as to maintain the phospholipid
`
`content (i.e., avoid phospholipid degradation) because Beaudoin I teaches the
`
`desirability of the recovery of total lipids.
`
`393. A person of skill in the art would have a reasonable expectation of
`
`success in arriving at the claimed invention because the methods of Beaudoin II are
`
`essentially the same as those described in the ‘351 patent. Thus, the concentration
`
`of lipids in the extracts resulting from the Beaudoin I extraction process would be
`
`essentially the same as the concentrations specified in the claims. The extracts
`
`could easily be made suitable for human consumption by rotary evaporation as
`
`described in Bergelson.
`
`(iii) Claims 1-94 are unpatentable under 35 USC 103(a) over Fujita (Ex.
`
`1005) in view of Watanabe (Ex. 1039), and further in view of Itano (Ex. 1009)
`
`and Yasawa (Ex. 1015).
`
`394. As discussed above, the declaratory evidence conclusively establishes
`
`the inherent presence of the claimed phospholipids in Fujita extracts from E.
`206
`
`
`
`00000206
`
`
`
`Inter Partes Review of US 8,278,351
`Ex. 1042, Brenna Declaration
`
`
`
`superba meal (claims 1, 19, 20 and 21), a fatty acid content of about 5% (Claim 4),
`
`PUFA and omega-3 content (claims 6 and 9) and the presence of Zn and Se in the
`
`Fujita extracts in the claimed amounts (claims 12-14). See Ground 4 and Claim
`
`Chart, supra. The remaining elements of claims 1 and 94 and dependent claims 2,
`
`3, 4, 22 and 23 (i.e., phospholipid content, triglycerides and other components, and
`
`astaxanthin) are explicitly disclosed in Fujita. Watanabe further describes
`
`properties of krill oil and a polar krill oil obtained by hexane extraction of krill
`
`meal (E. superba, Antarctic krill). See p. 682, col. 2, p. 685, col., 1, and p. 683
`
`Tables 1 and 2. Watanabe specifically discloses discloses the fatty acid
`
`composition (i.e., saturated and unsaturated fatty acids), free sterol (i.e.,
`
`cholesterol),
`
`fatty acid,
`
`
`
`triglyceride, diglyceride, monoglyceride, and
`
`sphingomyelin content of krill oil and krill polar oil extracts. These values are
`
`similar to those disclosed in the tables in dependent claims 15-18. Based on the
`
`similarity of these values, any values that are missing in Watanabe would be
`
`inherent. Itano describes concentrated krill phospholipid compositions. Itano at p.
`
`15. These compositions contained greater than 50% EPA and DHA, thus meeting
`
`the limitations of dependent claims 7 and 8 (>40% and 45% w/w PUFAs) and 10
`
`and 11 (>32% and 35% w/w DHA/EPA). Thus, the combined references meet
`
`each element of the claims, especially when none of the claimed concentrations of
`
`are critical as discussed above.
`
`
`
`207
`
`00000207
`
`
`
`Inter Partes Review of US 8,278,351
`Ex. 1042, Brenna Declaration
`
`395. Watanabe uses a hexane extraction from krill meal and acetone
`
`
`
`fractionation of phospholipids as described in Fujita. Itano discloses the
`
`desirability of krill phospholipids for use in foods and as nutritional supplements as
`
`well as specific concentrated krill phospholipid compositions. Yasawa describes
`
`different methods of formulating krill oil. A person of skill in the art would have
`
`been motivated to combine these four references because they teach methods for
`
`extraction and concentration of krill phospholipids and their incorporation into oral
`
`and topical dosage forms as well as into functional foods. There is a reasonable
`
`expectation of success because specific krill phospholipid extracts are disclosed
`
`that closely approximate the claimed values of the ‘351 krill extracts. Formulating
`
`the krill extracts so that they are suitable for human consumption and incorporating
`
`the extracts into oral and topical delivery forms and foods is well within the skill in
`
`the art.
`
`(iv) Claims 1-2 94 are unpatentable under 35 USC 103(a) over Fricke (Ex.
`
`1006) in view of Bergelson (Ex. 1017), and further in view of Yasawa (Ex.
`
`1015), Itano (Ex. 1009) and the WHO Bulletin (Ex. 1018)
`
`396. Claims 1-23 and 94 are obvious under 35 USC 103(a) over Fricke in
`
`view of Bergelson and further in view of Yasawa, Itano and the WHO Bulletin.
`
`The claim elements taught by Fricke are addressed above.
`
`
`
`208
`
`00000208
`
`
`
`Inter Partes Review of US 8,278,351
`Ex. 1042, Brenna Declaration
`
`397. Fricke specifically teaches that krill phospholipids have EPA (20:5 n-
`
`
`
`3) and DHA (22:6 n-3) at both sn-1 and sn-2 positions of PC and PE (See p. 826,
`
`Table 6), greater than 40% phospholipids (p. 821, Table 1) and greater than 15%
`
`omega-3 w/w (p. 823, Table 1). Le Grandois (Ex. 1013) further establishes that
`
`the claimed phospholipids are present in Folch extracts from krill oil. Thus, the
`
`Folch extraction technique is suitable for preserving the claimed phospholipids.
`
`Bergelson teaches removal of chloroform/methanol solvents from lipids by rotary
`
`evaporation. Thus, it was well within the skill of those in the art to produce
`
`extracts suitable for human consumption by the Folch extraction technique taught
`
`in Fricke. Yasawa (¶¶0008-19) and Itano (p. 16) further teach krill extracts that are
`
`suitable for human consumption (all claims), as well as incorporation of krill oil
`
`into capsules and syrups (Yasawa ¶¶0012-13; claims 24-46) and topical creams (¶¶
`
`Yasawa 0016; claims 70-93) and functional foods (Itano, p. 15; claims 47-69).
`
`Thus, the combined references teach each element of the independent claims.
`
`398. The Fricke extracts contained the claimed levels of phospholipids
`
`(claims 2, 3, 25, 26, 48, 49, 72, and 73; p. 82, Table 1 (from 39.6% to 42.5% intact
`
`phospholipids)), triglycerides and monoglycerides (claims 4, 27, 50 and 74; p. 822,
`
`Table 1), about 5% w/w free fatty acids (claims 5, 28, 51 and 75; p. 822, Table 1
`
`(extracts had from 8.5% to 16.1% free fatty acids)), at least 15% w/w PUFAs
`
`(claims 6, 29, 52, and 76; p. 823, Table 2 (sum of 24.02% PUFAs from table,
`209
`
`
`
`00000209
`
`
`
`Inter Partes Review of US 8,278,351
`Ex. 1042, Brenna Declaration
`
`
`
`1977 sample)), and at least 15% omega-3 fatty acids (claims 9, 32, 55, and 79; p.
`
`823, Table 2 (sum of 21.42% from table, 1977 sample)). Itano teaches
`
`concentrated krill phospholipid extracts having greater than 40% w/w and 45%
`
`w/w phospholipids (p. 16; claims 7, 8, 30, 31, 53, 54, 77, and 78) and greater than
`
`32% and 35% w/w EPA and DHA (p. 16; claims 10, 11, 33, 34, 56, 57, 80 and 81).
`
`The extracts inherently contained the claimed Zn and Se amounts as krill are well
`
`known to contain these elements (WHO Bulletin p. 551, col. 2; claims 12-14, 35-
`
`37, 58-60 and 82-84). With respect to the tables of components listed in claims 15-
`
`18, 38-41, 61-64 and 85-88, Fricke specifically discloses the fatty acid content of
`
`the phospholipid classes (See p. 24, Table 4; claims 15, 38, 61 and 85) and total
`
`lipids (See p. 823, Table 2; claims 16, 39, 62, and 86). Fricke likewise discloses
`
`mono-, di- and triglyceride content and the content of phosphatidylcholine,
`
`phosphatidylethanolamine, sphingomyelin, and cholesterol as well as other
`
`components including saturated, omega-3 and polyunsaturated fatty acid content.
`
`See p. 822, Table 1; p. 823, Table 2; p. 826, Table 7; claims 17, 18, 40, 41, 63, 64,
`
`87 and 88). The extracts inherently contained the claimed individual phospholipid
`
`species listed in claims 19-21, 42-44, 65-67 and 89-91 (See p. 826, Table 6,
`
`discussed above) as well as carotenoids (astaxanthin; claims 22, 23, 45, 46, 68, 69,
`
`92 and 93). Thus, the combined references meet each element of the claims,
`
`
`
`210
`
`00000210
`
`
`
`Inter Partes Review of US 8,278,351
`Ex. 1042, Brenna Declaration
`
`
`
`especially when none of the claimed concentrations of phospholipids and other
`
`lipid extract components are critical as discussed above.
`
`399. Fricke teaches extraction of E. superba with chloroform/methanol.
`
`Bergelson teaches removal of solvents such as chloroform/methanol by rotary
`
`evaporation under mild conditions. Yasawa and Itano teach the desirability of krill
`
`phospholipid compositions
`
`for human consumption, concentrated krill
`
`phospholipid compositions and topical and oral krill oil formulations. The WHO
`
`Bulletin teach the usefulness of krill for a variety of purposes including as a source
`
`of EPA, DHA, Zn, and Se. A person of skill in the art would have been motivated
`
`to combine these references because they teach methods for extraction and
`
`concentration of krill phospholipids and their incorporation into oral and topical
`
`dosage forms as well as into functional foods. There is a reasonable expectation of
`
`success because specific krill phospholipid extracts are disclosed that closely
`
`approximate the claimed values of the ‘351 krill extracts. Formulating the krill
`
`extracts so that they are suitable for human consumption and incorporating the
`
`extracts into oral and topical delivery forms and foods is well within the skill in the
`
`211
`
`art.
`
`
`
`
`
`00000211
`
`
`
`Inter Partes Review of US 8,278,351
`Ex. 1042, Brenna Declaration
`
`400. I further declare that all statement made herein of my own knowledge
`
`
`
`are true and that all statements made on information and belief are believed to be
`
`true; and further that these statements were made with the knowledge that willful
`
`false statements and the like so made are punishable by fine or imprisonment, or
`
`both, under section 1001 of title 18 of the United States Code, and that such willful
`
`false statements may jeopardize the validity of the application or any patent issued
`
`thereon.
`
`Respectfully submitted,
`
`
`
`
`
`
`
`212
`
`00000212
`
`
`
`J. Thomas Brenna, PhD
`
`Curriculum Vitae
`
`Educational and Professional
`
`2000-present Professor of Human Nutrition and of Chemistry and Chemical
`
`September 2013
`
`Biology. Division of Nutritional Sciences, Cornell University, Ithaca,
`
`New York, USA. 1989-1995 Assistant Professor; 1995-2000 Associ-
`
`ate Professor. Member of Cornell Graduate Faculties of Food Science
`
`and Technology, and of Geological Sciences. Since 2012, Professor
`
`of Food Science and Technology.
`
`2006-present Adjunct Professor, Dept of Public Health Sciences, University of
`
`Rochester College of Medicine and Dentistry, Rochester, New York.
`
`2001-2007 Director of Undergraduate Studies, Div of Nutritional Sci, Cornell Uni-
`
`versity, Ithaca, New York.
`
`1985-1989 Staff Scientist, Advanced Technology Development Laboratory, IBM
`
`Corporation, Endicott, NY. Founding Director of the Fourier Transform
`
`Mass Spectrometry Laboratory.
`
`1988-1989 Adjunct Assistant Professor, Dept of Chemistry, Binghamton Universi-
`
`ty, New York.
`
`1985/1982 PhD/MS Chemistry, Cornell University, Ithaca, NY. Thesis advisor: G.
`
`00000213
`
`
`
`Brenna
`H. Morrison.
`
`
`
`
`
`Page 2
`
`1980
`
`BS cum laude, Nutritional Biochemistry, University of Connecticut,
`
`Storrs. Undergrad Research Technician, Lipids Lab (with R. G. Jen-
`
`sen), Dept. of Nutr. Sci., UConn (1978-80).
`
`Professional Experience
`
`Summary: Principal Investigator, National Institutes of Health (NIH) since 1990
`
`(selected): National Institute for General Medical Sciences (R01
`
`GM103437/RR031264, 2010-15; other R01s, 2004-2009, 1992-2006); National
`
`Center for Complementary and Alternative Medicine/Office of Dietary Supple-
`
`ments (R01 AT007003, 2013-2018) NI of Child Health & Human Development
`
`(R21 & R03 2006-2010); National Eye Institute (R01, 1994-2003); United States
`
`Antidoping Agency; Partnership for Clean Competition; numerous industry/private
`
`grants. Our research laboratory averages 10-15 fulltime members and is focused
`
`on fatty acid metabolism, development of high precision isotopic, molecular, and
`
`elemental mass spectrometry for biomedical applications, and high precision iso-
`
`tope ratio mass spectrometry in doping control research.
`
`Author/co-author of >200 peer-reviewed publications; 1 U.S. patent/several pend-
`
`ing. >100 invited presentations
`
`2013 Robert H. Herman Award, American Society for Nutrition. “Given each year
`
`to a clinical investigator whose research work has contributed importantly to the
`
`00000214
`
`
`
`Brenna
`
`
`Page 3
`advancement of clinical nutrition, particularly the biochemical and metabolic
`
`aspects of human nutrition.”
`
`Scientific Service (recent, selected)
`
`• Member, 2015 Dietary Guidelines Advisory Committee. Appointed by US Sec-
`
`retaries of Health and Human Services and of Agriculture.
`
`• President, ISSFAL: International Society for the Study of Fatty Acids and Li-
`
`pids. 2012-2015 President-Elect; 2015-2018 President; 2019-2021 Past-
`
`President. Member, Board of Directors, 2001-2009
`
`• FAO/WHO Expert Consultation on Fats and Fatty Acids in Human Nutrition,
`
`Panelist & author, Geneva, Switzerland, 2008-11.
`
`• Research Proposal Reviews (selected):
`
` NIH: 2013, 2012 Metabolomics Core Facilities; 2010 Shared Research In-
`
`strumentation-Mass Spectrometry (Study Section Chairman); 2008 NIGMS
`
`Large Scale Collaboration (Glue grant) & P01; 2001-2007 Biol Chem & Mac-
`
`romolecular Biophysics Study Section. 2004 Metabolomics Panel, NIH Di-
`
`rector’s Roadmap; 2004 NCI Innovative Technologies for Molecular Analysis
`
`of Cancer; 1997, 2009 NIH Intramural Reviews
`
` World Antidoping Agency (WADA) Research grants program, 2012, 2007.
`
` NSF Major Research Instrumentation, Chemistry Division. 2006, 2004.
`
`00000215
`
`
`
`Brenna
`
`
`Page 4
` Louisiana Board of Regents Chemical Instrumentation Review Panel, 2008,
`
`2005, 2002.
`
`• Expert Witness (selected). Infant nutrition, Federal Court, Eastern District of
`
`Virginia (2009). Gas Chromatography (GC) and GC-combustion isotope ratio
`
`mass spectrometry (GCC-IRMS), American Arbitration Association (2007) and
`
`The Court of Arbitration for Sport (2008).
`
`• Meeting Co-organizer (selected). 2012. 28th ASMS Asilomar Conference:
`
`Mass Spectrometry in Food Safety and Quality. 2011. DHA in Translational
`
`Medicine. Fatty acids and cell signaling (FACS-10), New Orleans, LA (Guest
`
`Editor, Prostaglandins, Leukotrienes, and Essential Fatty Acids (PLEFA)).
`
`2010. A Celebration of DHA, London, UK. 2008. DHA as an Essential Nutri-
`
`ent, Co-editor of PLEFA Supplement. 2007. Fatty acids and cell signaling
`
`(FACS-8), Quebec City, Canada (Guest Editor, PLEFA 77(6): FACS-8 Pro-
`
`ceedings.) 2002, 6th Congress of ISSFAL, Montreal, Canada. Symposia: Li-
`
`pids and mass spectrometry. ASMS 1999 (Portland), 2008 (Denver); 2006
`
`(Cairns) ISSFAL; 2008 (Salt Lake) ABRF.
`
`• Scientific Advisory Boards. 2012-present, First Editor, British Journal of Nutri-
`
`tion; 2006-present, Fats of Life Newsletter
`
`<http://www.fatsoflife.com/index.php>; 2002-present, Editorial Advisory Board,
`
`Rapid Communications in Mass Spectrometry; 2011-present, Metabolism Unit -
`
`Mass Spectrometry Core Lab, Shriners Hospital for Children, Galveston. NY;
`
`00000216
`
`
`
`Brenna
`
`
`Page 5
`1999-present, NIH Center for Biomedical Accelerator Mass Spectrometry, Law-
`
`rence Livermore National Laboratory, Livermore, CA.
`
`• 2000-2004 Member, Publications Committee, American Society for Mass
`
`Spectrometry
`
`Selected Research Funding Awards as Principal Investigator (Total support as PI,
`
`1990-2010, >$15M total; active.)
`
`2013-18 Molecular Mechanism of Omega-3 Response, NIH-NCCAM/ODS (R01)
`
`2010-15 GCx(py)GCC-IRMS for Isotope Metabolomics, NIH-NIGMS (R01)
`
`
`
`2010-13 Branched Chain FA and Gut Development, NIH-Nat Inst Child Health &
`
`Hum Development (R21).
`
`2009-12 Characterization of the Human Urinary Steroidome, Partnership for
`
`Clean Competition.
`
`2006-10 LCPUFA Status and Birth Outcome in India, NIH-Nat Inst Child Health &
`
`Hum Development (R03).
`
`2004-09 Gas phase derivatization for lipidomic MS analysis, NIH-NIGMS (R01)
`
`2006-09 Standardization and Methodology for Steroid Isotopic Analysis, United
`
`States Anti-Doping Agency.
`
`2002-08 LCPUFA supplementation & CNS function, Mead Johnson & Co/Bristol-
`
`Myers Squibb, Evansville, IN.
`
`2005-06 Safety and efficacy of single cell oils, Martek Biosciences, Columbia,
`
`00000217
`
`
`
`Brenna
`MD.
`
`
`
`
`
`Page 6
`
`1992-06 Precise isotope ratio chromatography and stable tracers, NIH-NIGMS
`
`(R01) (incl 2 competitive renewals).
`
`1994-03 Dietary essential fatty acid accumulation in retina, NIH-National Eye
`
`Institute (R01) (incl 1 competitive renewal).
`
`2002-03 Conjugated linoleic acid metabolism in humans, National Cattlemans
`
`Beef Association.
`
`1999-00 Matrix-assisted laser desorption/ionization mass spectrometer, Na-
`
`tional Science Foundation.
`
`1995-99 Natural abundance isotope center, NSF & Mellon Foundation.
`
`1993-94
`
`13C-tracers for environmental analysis, Oak Ridge National Laboratory.
`
`Tennessee.
`
`1991-93 Novel determination of water isotopes, American Chemical Society-
`
`Petroleum Research Fund.
`
`1990-92 Novel water isotope detection by mass spectrometry, NIH-National In-
`
`stitute of Child Health & Human Dev (R03).
`
`Professional Society Memberships:
`
`ASMS: American Society for Mass Spectrometry; ASN: American Society for Nu-
`
`trition; ISSFAL: International Society for the Study of Fatty Acids and Lipids.
`
`ASBMB: American Society for Biochemistry and Molecular Biology. American
`
`Chemical Society 25 year member.
`
`00000218
`
`
`
`Brenna
`
`University/College/Department Service (selected) and Teaching
`
`
`
`Page 7
`
`• Teaching.
`
` Undergraduate. 2012, ongoing: NS 4444, Sports Nutrition and Supple-
`
`ments: Concept and Evidence. 2000-2010: Research in Health and Nutri-
`
`tion; 2000-2010: Undergraduate Honors program director; 1991-2001: NS
`
`332 Methods in Nutritional Science
`
` Graduate. 1992-present: NS 6900/Chem 6280 Isotopic and Trace Element
`
`Analysis. 1988: Binghamton University Graduate Course: Advanced Instru-
`
`mental Surface Characterization.
`
`• Service
`
` Cornell University Athletics: 2007-2010; 1997-2000; 1992-1995 Faculty
`
`Advisory Committee on Athletics and Physical Education (Chair 1993/1994;
`
`1994/1995; 1997/1998). 1998/1999 NCAA Cornell Rev Steering Committee;
`
`1994/1995 Cornell Athletic Director Search. 1998-2013 Cornell Varsity
`
`Softball, Faculty Advisor
`
` University Mass Spectrometry facilities
`
` 1999, Co-Founder, Cornell Biotechnology proteomics/small molecule
`
`mass spectrometry facility, funded by an NIH shared instrumentation
`
`grant (PI). Currently designated faculty facility advisor.
`
` 1995, Co-Founder, Cornell Isotope Laboratory (COIL), an isotope ratio
`
`00000219
`
`
`
`Brenna
`
`
`
`Page 8
`mass spectrometry service facility funded by NSF and the Mellon Foun-
`
`dation (one of 5 PIs).
`
` University (other): 2013-2015, 2001-2004, 1994-1995 Cornell Faculty
`
`Senate; 1994-1995 Dean’s Committee on Faculty Governance.
`
` College: 2001-2007 College of Human Ecology Educational Policy Com-
`
`mittee; 2006/07 Chair; 1995/1996, Chair 1996/1997 & 1997/1998 Col of
`
`Human Ecology Committee on Academic Status
`
`00000220
`
`
`
`Brenna
`
`Publications
`
`
`
`
`
`Page 9
`
`I. Peer Reviewed Journal Articles/Book Chapters/Gene Sequence post-
`
`ings/Letters and comments
`
`II. Selected Invited Lectures
`
`III. General/Popular Press Articles
`
`IV. Conference Presentations/Abstracts/Extended Abstracts
`
`I. Peer Reviewed Journal Articles/Book Chapters/ Gene Sequence postings
`
`(>200 total)
`
`Comment on Rizos et al., JAMA 2012, September 12 ; 308(10):1024-1033. Clau-
`
`dio Galli and J. Thomas Brenna. Journal of the American Medical Association
`
`309(1): 27, 2013.
`
`Fatty Acid Analysis By High Resolution Gas Chromatography and Mass Spec-
`
`trometry for Clinical and Experimental Applications. J. Thomas Brenna. Current
`
`Opinion
`
`in Clinical Nutrition and Metabolic Care, 2013;16(5):548-54. doi:
`
`10.1097/MCO.0b013e328363bc0a. PMID: 23892505.
`
`Branched Chain Fatty Acids (BCFA) in the neonatal gut, and estimated dietary in-
`
`take in infancy and adulthood. Rinat R. Ran-Ressler, Raymond P Glahn,
`
`SangEun Bae, J. Thomas Brenna, Nestlé Nutrition Institute Workshops Series 77,
`
`2013, in press.
`
`00000221
`
`
`
`Brenna
`
`
`Page 10
`Disturbance in uniformly 13C-labelled docosahexaenoic acid metabolism in elderly
`
`humans carrying apolipoprotein E4 allele. Chouinard-Watkins R, Rioux-Perreault
`
`C, Fortier M, Tremblay-Mercier J, Zhang Y, Lawrence P,Vohl MC, Perron P, Lor-
`
`rain D, Brenna JT, Cunnane SC, Plourde M. British Journal of Nutrition 2013, in
`
`press.
`
`Plasma Oxylipin Profiling Identifies Polyunsaturated Vicinal Diols As Responsive
`
`To Arachidonic Acid (ARA) And Docosahexaenoic Acid (DHA) Intake In Growing
`
`Piglets. MJ Bruins, AD Dane, K Strassburg, RJ Vreeken, JW Newman, N Salem
`
`Jr, C Tyburczy, JT Brenna, Journal of Lipid Research 2013, Jun;54(6):1598-607.
`
`PMID: 23543770; PubMed Central PMCID: PMC3646461.
`
`Docosahexaenoic Acid and Human Brain Development: Evidence A Dietary Sup-
`
`ply is Needed for Optimal Development. J. Thomas Brenna, Susan E. Carlson.
`
`The Journal of Human Evolution, in press, 2013.
`
`Interruption of scheduled, automatic feeding and reduction of excess energy in-
`
`take in toddlers. Ciampolini M, Brenna JT, Giannellini V, Bini S. International
`
`Journal of General Medicine. 2013;6:39-47. PMID: 23393411 [PubMed] PMCID:
`
`PMC3565931 doi: 10.2147/IJGM.S39946. Epub 2013 Jan 31.
`
`Effects of Low-Dose Aspirin and Fish Oil on Platelet Function and NFkappaB in
`
`Adults with Diabetes Mellitus, Robert C Block, Amir Abdolahi, Brian Smith, N
`
`Meednu, Kelly Thevenet-Morrison, Xueya Cai, Huadong Cui, Shaker Mousa, J.
`
`00000222
`
`
`
`Brenna
`
`
`Page 11
`Thomas Brenna, S Georas, Prostaglandins, Leukotrienes, and Essential Fatty Ac-
`
`ids, 2013, 89(1):9-18. PMCID: PMC3589139. PMID: 23664596.
`
`Commentary on ‘Maternal long-chain PUFA supplementation during protein defi-
`
`ciency improves brain fatty acid accretion in rat pups by altering the milk fatty acid
`
`composition of the dam’, J. T. Brenna. Journal of Nutritional Sciences 2:e4, 2013.
`
`Steric Effects in the interaction between Transmembrane Proteins and Polyun-
`
`saturated Phospholipids. Khatuna Kachlishvili and J. Thomas Brenna, Journal of
`
`Biological Physics and Chemistry, 2013; 13: 36-44.
`
`Pregnancy alters choline metabolism in women consuming methyl-d9-choline.
`
`Jian Yan, Xinyin Jiang, Allyson A. West, Cydne A. Perry, Olga V. Malysheva, J
`
`Thomas Brenna, Sally P. Stabler, Robert H. Allen, Marie A. Caudill. Submitted,
`
`2013.
`
`Isotope Protection of Polyunsaturated Fatty Acids against Lipid Peroxidation: a
`
`Novel Approach to Mitigating Mitochondrial Neurological Diseases. Mikhail S.
`
`Shchepinov, Vitaly A. Roginsky, J. Thomas Brenna, Robert J. Molinari, Randy To,
`
`Hui Tsui, Catherine F. Clarke and Amy B. Manning-Boǧ. Submitted, 2013.
`
`Dietary arachidonic acid and docosahexaenoic acid regulate liver fatty acid de-
`
`saturase (FADS) alternative transcript expression in suckling piglets. Vasuki Wi-
`
`jendran, Ian Downs, Cynthia Tyburczy, Kumar S. D. Kothapalli, Woo Jung Park,
`
`00000223
`
`
`
`Brenna
`
`
`Page 12
`Bryant S. Blank, J. Paul Zimmer, C.M. Butt, Norman Salem, Jr., J. Thomas Bren-
`
`na, Prostaglandins, Leukotrienes, and Essential Fatty Acids, 2013, in press.
`
`Metabolism of 13C-docosahexaenoic acid before and after fish oil supplementa-
`
`tion in healthy older individuals. Plourde M, Chouinard-Watkins R, Rioux-
`
`Perreault C, Fortier M, Dang TM, Allard MJ, Tremblay-Mercier J, Zhang Y, Law-
`
`rence P, Vohl MC, Perron P, Lorrain D, Brenna JT, Cunnane SC, 2013, submitted.
`
`A novel FADS1 isoform potentiates FADS2-mediated production of eicosanoid
`
`precursor fatty acids.. Woo Jung Park, Kumar S.D. Kothapalli, Holly T. Reardon,
`
`Peter Lawrence, Shu-Bing Qian, J. Thomas Brenna, Journal of Lipid Research
`
`53(8):1502-12, 2012. PMID: 22619218.
`
`Insertion-deletions in a FADS2 intron 1 conserved regulatory locus control expres-
`
`sion of fatty acid desaturases 1 and 2 and modulate response to simvastatin. Hol-
`
`ly T. Reardon, Jimmy Zhang, Kumar S.D. Kothapalli, Andrea J. Kim, Woo Jung
`
`Park, and J. Thomas Brenna, PLEFA 2012, 87(1) 25-33. PMID: 22748975.
`
`Structural Characterization of Saturated Branched Chain Fatty Acid Methyl Esters
`
`by Collisional Dissociation of Electron Impact Activated Molecular Ions. Rinat
`
`Ran-Ressler, Peter Lawrence, J. Thomas Brenna, Journal of Lipid Research
`
`53(1):195-203, 2012. PMID: 22021637.
`
`Production of isotopically-labeled standards from a uniformly labele